Literature DB >> 11086121

T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism.

Nathalie Dejucq1, Graham Simmons1, Paul R Clapham1.   

Abstract

Changes in co-receptor-use by human immunodeficiency virus type 1 (HIV-1) strains are relatively rare in vivo. Here we describe two variants derived from the CCR5-using strain SF162, selected for replication in the C8166 T-cell line. Amino acid substitutions in the V3 loop conferred CXCR4-use; however, the loss of macrophage-tropism by one variant was due to a single mutation in the start codon of vpu. We discuss how V3 loop and vpu mutations acquired by replication in T-cell lines in vitro correlate with similar changes reported for primary isolates and HIV-1 sequences in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086121     DOI: 10.1099/0022-1317-81-12-2899

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

Authors:  Joshua M Farber; Edward A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

2.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism.

Authors:  Brian P Doehle; Kristina Chang; Arjun Rustagi; John McNevin; M Juliana McElrath; Michael Gale
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

4.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 5.  T cell virological synapses and HIV-1 pathogenesis.

Authors:  Benjamin K Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

6.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.

Authors:  Boris Julg; Amarendra Pegu; Peter Abbink; Jinyan Liu; Amanda Brinkman; Katherine Molloy; Shanell Mojta; Abishek Chandrashekar; Katherine Callow; Keyun Wang; Xuejun Chen; Stephen D Schmidt; Jinghe Huang; Richard A Koup; Michael S Seaman; Brandon F Keele; John R Mascola; Mark Connors; Dan H Barouch
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Specific VpU codon changes were significantly associated with gp120 V3 tropic signatures in HIV-1 B-subtype.

Authors:  Salvatore Dimonte; Muhammed Babakir-Mina; Stefano Aquaro; Carlo-Federico Perno
Journal:  Virol Sin       Date:  2012-12-28       Impact factor: 4.327

9.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

10.  Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.

Authors:  Wuze Ren; Silvana Tasca; Ke Zhuang; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.